Overview

Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain

Status:
Terminated
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
The prodrug, 5-Aminolevulinic acid (ALA), has been shown to lead to intracellular accumulation of fluorescent porphyrins in high grade malignant gliomas in the brain. On imaging, this accumulation of fluorescent porphyrins helps delineate tumor borders, resulting in the surgeon being better able to visualize and thus able to make a complete, or near-complete resection of the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
Aminolevulinic Acid